Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Istradefylline containing pharmaceutical composition

A kind of technology of istraphylline and composition, applied in the field of pharmaceutical composition containing istraphylline

Inactive Publication Date: 2016-12-14
合肥美利康医药技术股份有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the data, the incidence of Parkinson's disease is slightly higher in men than in women. So far, there is no radical cure for the recovery of degenerated nerve cells. The treatment of this disease is symptomatic treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] A pharmaceutical composition containing istradefylline, prepared from the following raw materials in parts by weight: istradefylline: 20 parts, puerarin: 10 parts, starch: 5 parts, low-substituted hydroxypropyl cellulose: 1 part, magnesium stearate: 2 parts, antioxidant: 2 parts, mannitol: 3 parts, micronized silica gel: 2 parts, chitin: 2 parts, sodium alginate: 2 parts, lactose: 3 parts;

[0017] Preparation process: Weigh the prescription amount of istradefylline, puerarin, starch, low-substituted hydroxypropyl cellulose, magnesium stearate, antioxidant, mannitol, micropowder silica gel, chitin, sodium alginate, lactose and mix uniform. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with t...

Embodiment 2

[0019] A pharmaceutical composition containing istradefylline, prepared from the following raw materials in parts by weight: istradefylline: 50 parts, puerarin: 20 parts, starch: 12 parts, low-substituted hydroxypropyl cellulose: 9 parts, magnesium stearate: 6 parts, antioxidant: 8 parts, mannitol: 5 parts, micronized silica gel: 10 parts, chitin: 10 parts, sodium alginate: 8 parts, lactose: 10 parts;

[0020] Preparation process: Weigh the prescription amount of istradefylline, puerarin, starch, low-substituted hydroxypropyl cellulose, magnesium stearate, antioxidant, mannitol, micropowder silica gel, chitin, sodium alginate, lactose and mix uniform. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix w...

Embodiment 3

[0022] A pharmaceutical composition containing istradefylline, prepared from the following raw materials in parts by weight: istradefylline: 25 parts, puerarin: 12 parts, starch: 6 parts, low-substituted hydroxypropyl cellulose: 2 parts, magnesium stearate: 4 parts, antioxidant: 3 parts, mannitol: 3 parts, micronized silica gel: 3 parts, chitin: 4 parts, sodium alginate: 3 parts, lactose: 6 parts;

[0023] Preparation process: Weigh the prescription amount of istradefylline, puerarin, starch, low-substituted hydroxypropyl cellulose, magnesium stearate, antioxidant, mannitol, micropowder silica gel, chitin, sodium alginate, lactose and mix uniform. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an istradefylline containing pharmaceutical composition. The composition is prepared from, by weight, 20-50 parts of istradefylline, 10-20 parts of puerarin, 5-12 parts of starch, 1-9 parts of low-substituted hydroxypropyl cellulose, 2-6 parts of magnesium stearate, 2-8 parts of antioxidant, 3-5 parts of mannitol, 2-10 parts of superfine silica powder, 2-10 parts of chitosan, 2-8 parts of sodium alginate and 3-10 parts of lactose. A preparation process of the composition includes the steps of weighing and evenly mixing istradefylline, puerarin, starch, low-substituted hydroxypropyl cellulose, magnesium stearate, antioxidant, mannitol, superfine silica powder, chitosan, sodium alginate and lactose according to the amounts in the formula, additionally adding a proper amount of 60% ethyl alcohol to mixed powder to be evenly mixed to prepare a soft material, conducting granulating through a 16-mesh screen, conducting drying at 60 DEG C or below, conducting size stabilizing after drying is completed, evenly mixing granules with dry particles, and conducting tabletting to obtain the composition. The composition has the advantage of treating the Parkinson's disease.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition containing istradefylline. Background technique [0002] Parkinson's disease, also known as parkinsonism, is the most common degenerative disease of the central nervous system in middle-aged and elderly people. Tremor refers to the trembling and shaking of the head and limbs, and paralysis refers to the inability of a part or all of the limbs to move voluntarily, including movement disorders, tremors, and muscle stiffness. As my country gradually enters into an aging population society, its incidence rate has been increasing year by year in recent years, and the incidence rate gradually increases with age. The age of onset generally begins at the age of 50 to 65. The incidence rate at the age of 60 is about 1‰, and at the age of 70 it reaches 3‰ to 5‰. There are currently more than 1.7 million people suffering from this disease in China. Data show ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/522A61P25/16A61K47/38A61K47/36A61K47/26A61P25/28A61K31/352
CPCA61K31/522A61K9/2018A61K9/2054A61K9/2059A61K31/352A61K2300/00
Inventor 赵冬生方从彬方存杰孙明哲孙延标徐奎
Owner 合肥美利康医药技术股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com